The Department of Health and Human Services, Office of the Secretary publishes a list of information collections it has submitted to the Office of Management and Budget (OMB) for clearance in compliance with the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) and 5 CFR 13320.5. The following are those information collections recently submitted to OMB.
1. Protection of Human Subjects: Assurance Identification/Certification/ Declaration-NEW-This form, which will replace Optional Form 310, is a sample format which may be used by some entities to comply with the requirements of Section l.103(f) of the Common Rule, which requires that institutions submitting applications for Federal support of research involving human subjects submit certification of appropriate Institutional Review Board review and approval. The burden for use of this form, estimated to be 5 minutes, is included under total burden for the Common Rule, approved under OMB Clearance Number 0990-0260.
OMB Desk Officer: Allison Herron Eydt.
Copies of the information collection packages listed above can be obtained by calling the OS Report Clearance Officer on (202) Dr. Tracy's doctoral research at UCD involved the analysis of the mechanisms used by various enzymes to repair damaged DNA, while his postdoctoral research at USC dealt with the molecular mechanism used by Blymphocytes when switching from producing one class of immunoglobulin to another.
Specifically, PHS found that:
(1) In 1996 and 1997, Dr. Tracy falsified research supported by NIH grant R01 AI18987, ''Mechanistic studies of genetic recombination,'' while working on his doctoral dissertation at UCD. Dr. Tracy falsified Figure 6 .2 of his Ph.D. thesis by adding discrete bands where there actually had only been a uniform smear of radioactivity, the effect being to suggest a result that had not been observed and was, therefore, falsified. The falsified image was not published.
(2) From 1998 to 2000, Dr. Tracy committed additional scientific misconduct while a postdoctoral fellow at USC in research funded by NIH grant R01 GM56984 ''Mechanism of DNA recombination at class switch sequences.'' Dr. Tracy falsified values in generally provide that a patent may be extended for a period of up to 5 years so long as the patented item (human drug product, animal drug product, medical device, food additive, or color additive) was subject to regulatory review by FDA before the item was marketed. Under these acts, a product's regulatory review period forms the basis for determining the amount of extension an applicant may receive.
A regulatory review period consists of two periods of time: A testing phase and an approval phase. For human drug products, the testing phase begins when the exemption to permit the clinical investigations of the drug becomes effective and runs until the approval phase begins. The approval phase starts with the initial submission of an application to market the human drug product and continues until FDA grants permission to market the drug product. Although only a portion of a regulatory review period may count toward the
